Articles from DSS, Inc.

DSS, Inc. Announces SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination

Special meeting of Impact Biomedical stockholders to approve the proposed Business Combination scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard TimeUpon closing, the combined company is expected to operate as Zoar Limited and trade on NYSE American under the ticker symbol "ZOAR," subject to listing approval

By DSS, Inc. · Via ACCESS Newswire · November 2, 2026

Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled "Low Glycemic Sugar Composition" developed within this platform.

By DSS, Inc. · Via GlobeNewswire · January 30, 2024